ArriVent BioPharma
Clinical-stage biopharmaceutical company developing precision therapies for cancer patients, with a focus on lung cancer and other solid tumors with specific genetic drivers.
Notes
ArriVent BioPharma is a clinical-stage biopharmaceutical company focused on developing precision cancer therapies for patients with genetically defined tumors. The company's lead program, furmonertinib, is a third-generation EGFR tyrosine kinase inhibitor (TKI) for the treatment of non-small cell lung cancer (NSCLC) with EGFR mutations.
ArriVent's strategy focuses on bringing innovative cancer therapies that have shown promise in other markets to patients in the United States and globally. The company has secured rights to develop and commercialize therapies for specific geographic regions.
The company went public in 2024 and is traded on NASDAQ. ArriVent is backed by leading healthcare investors including Novo Holdings.
Team
- Huamao (Eric) Wang, Ph.D. - Founder, Chairman & Chief Executive Officer
- LinkedIn: linkedin.com/in/huamaowang
- Corey Goodman, Ph.D. - Board Member
- James Healy, M.D., Ph.D. - Board Member
Additional Research Findings
- NASDAQ listed company (AVBP)
- Lead program furmonertinib (third-generation EGFR TKI)
- Focus on NSCLC with EGFR mutations
- Investor: Novo Holdings
- IPO in 2024
- Irvine, California headquarters
- Founded 2021
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| Novo Holdings | Hellerup, Denmark | biotech-focused | seedseries-a+3 | 13 |